Metastatic colorectal carcinoma patients: The Glasgow Prognostic Score (GPS) at the era of anti-EGFR therapies

被引：0
|
作者：
Dreanic, J. [1 ]
Maillet, M. [1 ]
Dhooge, M. [1 ]
Cessot, A. [2 ]
Mir, O. [2 ]
Brezault, C. [1 ]
Goldwasser, F. [2 ]
Chaussade, S. [1 ]
Coriat, R. [1 ]
机构：
[1] Paris Descartes Univ, Cochin Teaching Hosp, AP HP, Dept Gastroenterol, Paris, France
[2] Paris Descartes Univ, Cochin Teaching Hosp, AP HP, Dept Oncol, Paris, France
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2290
引用
收藏
页码：S525 / S525
页数：1
相关论文
共 50 条
  • [11] Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
    Lo Nigro, Cristiana
    Ricci, Vincenzo
    Vivenza, Daniela
    Granetto, Cristina
    Fabozzi, Teresa
    Miraglio, Emanuela
    Merlano, Marco C.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (30) : 6944 - 6954
  • [12] Nanofluidic digital PCR for improved selection of metastatic colorectal cancer patients to anti-EGFR therapies
    Azuara, D.
    Santos, C.
    Lopez-Doriga, A.
    Montal, R.
    Sanjuan, X.
    Moreno, V.
    Tabernero, J.
    Montagut, C.
    Salazar, R.
    Capella, G.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S154 - S155
  • [13] Validation of KRAS Testing for Anti-EGFR Therapeutic Decisions for Patients With Metastatic Colorectal Carcinoma
    Kamel-Reid, Suzanne
    Zhang, Tong
    Persons, Diane L.
    Nikiforova, Marina N.
    Halling, Kevin C.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (01) : 26 - 32
  • [14] Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
    Liu, X.
    George, G. C.
    Tsimberidou, A. M.
    Naing, A.
    Wheler, J. J.
    Kopetz, S.
    Fu, S.
    Piha-Paul, S. A.
    Eng, C.
    Falchook, G. S.
    Janku, F.
    Garrett, C.
    Karp, D.
    Kurzrock, R.
    Zinner, R.
    Raghav, K.
    Subbiah, V.
    Hess, K.
    Meric-Bernstam, F.
    Hong, D. S.
    Overman, M. J.
    BMC CANCER, 2015, 15
  • [15] Validation of KRAS Testing for Anti-EGFR Therapeutic Decisions for Patients With Metastatic Colorectal Carcinoma
    Idowu, Michael O.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2013, 137 (02) : 155 - 155
  • [16] KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
    Soulieres, D.
    Greer, W.
    Magliocco, Anthony M.
    Huntsman, D.
    Young, S.
    Tsao, M-S.
    Kamel-Reid, S.
    CURRENT ONCOLOGY, 2010, 17 : S31 - S40
  • [17] Glasgow Prognostic Score (GPS) Can Be a Useful Indicator to Determine Prognosis of Patients With Colorectal Carcinoma
    Nozoe, Tadahiro
    Matono, Rumi
    Ijichi, Hideki
    Ohga, Takefumi
    Ezaki, Takahiro
    INTERNATIONAL SURGERY, 2014, 99 (05) : 512 - 517
  • [18] Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
    Fakih, M.
    Vincent, M.
    CURRENT ONCOLOGY, 2010, 17 : S18 - S30
  • [19] Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
    X. Liu
    G. C. George
    A. M. Tsimberidou
    A. Naing
    J. J. Wheler
    S. Kopetz
    S. Fu
    S. A. Piha-Paul
    C. Eng
    G. S. Falchook
    F. Janku
    C. Garrett
    D. Karp
    R. Kurzrock
    R. Zinner
    K. Raghav
    V. Subbiah
    K. Hess
    F. Meric-Bernstam
    D. S. Hong
    M. J. Overman
    BMC Cancer, 15
  • [20] Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
    Jose A. García-Sáenz
    Javier Sastre
    Eduardo Díaz-Rubio García
    Clinical and Translational Oncology, 2009, 11 : 737 - 747
12345